Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy With Asunaprevir, Daclatasvir and BMS-791325 in HCV Genotype 4 After Peg-IFN/RBV Failure
NCT02309450Phase 2Withdrawn
- Sponsor
- ANRS
- Start
- Dec 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of asunaprevir, daclatasvir, beclabuvir in hepatitis C virus infection, sponsored by ANRS. Planned start Dec 2014; status: withdrawn.
02
Drugs
asunaprevirdaclatasvirbeclabuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02309450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309450.